Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Asparaginase + Cyclophosphamide + Etoposide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Asparaginase||Elspar||L-asparaginase|ASP-1||Elspar (asparaginase) is an enzyme that converts L-asparagine to L-aspartic acid and ammonia, reducing the available L-asparagine, which may result in cell-cycle arrest and apoptosis in leukemia cells (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin||TOPO2 inhibitor 4||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02101853||Phase III||Blinatumomab Leucovorin + Pegaspargase + Vincristine Mercaptopurine + Thioguanine Asparaginase + Cyclophosphamide + Etoposide Cytarabine + Dexamethasone + Methotrexate||Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia||Active, not recruiting|